Short answer
Tevogen Bio Holdings Inc. (TVGN) filed its Q2 2026 10-Q quarterly report on Aug 14, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$6M
- −4.7% YoY · −5.8% QoQ
- EPS (diluted)
- −$1.55
- −7650.0% YoY · +3.7% QoQ
Source: XBRL data from the Tevogen Bio Holdings Inc. (TVGN) Q2 2026 10-Q on SEC EDGAR. USD.
Tevogen Bio Holdings Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product revenue generated to date
- Net loss $5.8M vs $5.5M YoY; operating loss $5.7M vs $5.4M
- R&D expenses $3.3M vs $2.7M; G&A expenses $2.4M vs $2.7M
- Cash $1.1M at June 30; $3.0M PIPE completed May 15
- Sufficient funding for at least 12 months; R&D expenses expected to increase significantly over several years
Risk Factors
- Newly added Nasdaq listing risk triggered by April 2026 deficiency notices for $50 million MVLS and $15 million MVPHS requirements
- Most material update: Nasdaq compliance deadlines of October 13, 2026 and October 14, 2026
- Regulatory risk: failure to regain compliance could delist common stock and public warrants from Nasdaq
- Market risk: delisting could reduce security liquidity and impair investors’ ability to trade
- Financial risk: no material changes disclosed from the Annual Report’s liquidity, debt, or currency risks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tevogen Bio Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.